NCT02670044 - A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2016

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Cobimetinib

Cobimetinib will be administered orally as per schedule in Arm description.

DRUG

Idasanutlin

Idasanutlin will be administered orally as per schedule in Arm description.

DRUG

Venetoclax

Venetoclax will be administered orally as per schedule in Arm description.

Trial Locations (17)

100

Universita di Roma, Roma

10065

Weill Cornell Medical College, New York

13009

Institut Paoli Calmettes, Marseille

27157

Wake Forest Baptist Medical Center, Winston-Salem

33600

CHU de Bordeaux, Pessac

40126

University of Bologna, Bologna

61122

Presidio san salvatore muraglia, Pesaro

77030

MD Anderson Cancer Center, Houston

90033

USC Norris Cancer Center, Los Angeles

93009

Hopital Avicenne, Paris, Bobigny

94143

Univ of Calif, San Francisco, San Francisco

95817

UC Davis; Comprehensive Cancer Center, Sacramento

80045-2517

University of Colorado, Aurora

02215

Dana Farber Cancer Institute, Boston

T6G 1Z1

University of Alberta Hospital, Edmonton

M5G 1Z5

Princess Margaret Cancer Center, Toronto

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY